Life sciences technology startup Graph AI has raised $3 million in seed funding led by Bessemer Venture Partners, marking a key milestone in its mission to enhance pharmacovigilance and patient safety through artificial intelligence.
The newly raised capital will be used to strengthen engineering, accelerate product innovation, and expand enterprise operations across global markets. The company also plans to enhance its AI platform capabilities to serve large pharmaceutical clients and regulatory partners more effectively.
Founded in 2024 by Raghav Parvataraju, Vijay Ponukumati, Mohan Konyala, and Ashutosh Bordekar, Graph AI operates within the $8 billion global pharmacovigilance market, which focuses on monitoring and reporting adverse drug events throughout a drug’s lifecycle. The founding team brings deep expertise from technology and healthcare giants such as Infosys, LTI Mindtree, Google, Cisco, and ServiceNow.
Graph AI’s flagship platform, Graph Safety, uses advanced AI automation to streamline pharmacovigilance workflows — from adverse event case processing and signal detection to compliance reporting. By replacing manual processes with intelligent automation, the platform improves data accuracy, ensures audit readiness, and reduces regulatory turnaround times.
The company has already onboarded several enterprise clients, reporting measurable improvements in operational efficiency and compliance speed. Building on this early momentum, Graph AI plans to scale globally, tapping into a growing market that tracks over 7,000 marketed drugs worldwide.
